Teleflex (NYSE:TFX) Given New $125.00 Price Target at Royal Bank Of Canada

Teleflex (NYSE:TFX) had its price target upped by research analysts at Royal Bank Of Canada from $115.00 to $125.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “sector perform” rating on the medical technology company’s stock. Royal Bank Of Canada’s target price points to a potential upside of 2.47% from the stock’s previous close.

A number of other research firms also recently issued reports on TFX. Wall Street Zen downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Wells Fargo & Company lifted their target price on shares of Teleflex from $116.00 to $130.00 and gave the company an “equal weight” rating in a report on Friday. Needham & Company LLC upped their price target on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday. Truist Financial raised their price target on Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $140.63.

Teleflex Trading Up 2.5%

Shares of TFX stock traded up $2.97 during trading on Friday, hitting $121.99. 677,505 shares of the stock traded hands, compared to its average volume of 1,059,447. The firm has a market capitalization of $5.39 billion, a P/E ratio of -16.62, a price-to-earnings-growth ratio of 1.46 and a beta of 0.92. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.57 and a quick ratio of 1.53. The firm’s fifty day moving average price is $111.34 and its 200-day moving average price is $118.68. Teleflex has a 52-week low of $100.18 and a 52-week high of $143.32.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing the consensus estimate of $3.73 by ($1.80). Teleflex had a positive return on equity of 15.64% and a negative net margin of 10.28%.The business had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $912.57 million. During the same quarter in the previous year, the company posted $3.89 earnings per share. The company’s revenue was down 28.5% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts forecast that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Teleflex by 57.9% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares in the last quarter. Banque Cantonale Vaudoise increased its holdings in Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after buying an additional 113 shares during the last quarter. Hantz Financial Services Inc. raised its stake in Teleflex by 248.8% in the third quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after buying an additional 199 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Teleflex during the 3rd quarter worth about $35,000. Finally, True Wealth Design LLC boosted its position in shares of Teleflex by 10,333.3% during the 2nd quarter. True Wealth Design LLC now owns 313 shares of the medical technology company’s stock worth $37,000 after acquiring an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

More Teleflex News

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Board approved a multi‑year restructuring to support planned divestitures and portfolio reshaping; the plan is intended to lower costs and streamline the business, which investors may view as a credible path to restore growth and margins. Teleflex Launches Multi-Year Restructuring to Support Divestitures
• Positive Sentiment: Board declared a quarterly cash dividend of $0.34 per share (payable March 31; record March 6), providing income support and signaling confidence in cash generation through the transition. Teleflex Announces Quarterly Dividend
• Neutral Sentiment: Company released the earnings presentation and held the earnings call — these contain management’s rationale, timing for divestitures, and details on cost actions; useful for investors who want to vet assumptions behind guidance. Teleflex Incorporated 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: Q4 results missed materially — GAAP/adjusted EPS and revenue both fell short (quarterly revenue ~$569M, down ~28.5% YoY) and margins compressed; the miss reflects weak continuing operations and hit near‑term earnings power. Teleflex (TFX) Q4 Earnings and Revenues Miss Estimates
• Negative Sentiment: Management cut FY‑2026 outlook sharply (EPS guidance $6.25–$6.55 vs. consensus ~15.18; revenue guide ~ $2.3B vs. est ~$3.7B), signaling a major reset in expected results — the guidance downgrade is the primary driver of near‑term downside risk. Teleflex Reports 2025 Financial Results and Full Year 2026 Outlook

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.